Our goal is to help humanity win the war
against age-related diseases

MISSION
Unlike most current compensatory therapies aimed at reducing the symptoms of age-related diseases, the therapies we are developing are aimed at their very causes — molecular and cellular damage that accumulates in the human body during life.
We put damage repair approach forward for the better world. The world without illness and ageing.
IntraClear Biologics is a new generation bioengineering company. Our goal is to help humanity put ageing under full medical control.
SCIENCE
As a result of normal metabolism, many by-products are formed in our body. Normally, almost all such products are removed using various repair mechanisms. However, some of them cannot be removed from the cells and extracellular space. Over time, they accumulate and lead to disruption of the normal function of cells and tissues, impair the metabolism and cause various diseases.
Lipofuscin consists of oxidized and peroxidized phospho- and glycolipids, proteins and heavy metal ions, "glued" together. It is also known as the "aging pigment".

The problem is that lipofuscin accumulates not only in the skin, but also in all cells of the body, especially in the brain and muscles. The accumulation of lipofuscin is associated with many age-related diseases, including neurodegenerative, neuromuscular, chronic inflammation and many others [1].
7-ketocholesterol (oxidized cholesterol) is a toxic oxysterol resulting from the reaction of a cholesterol molecule with a free oxygen radical. 7KC is difficult to extract once it is in the cell.

It is very toxic and is the main damaging molecule involved in many age-related diseases, including atherosclerosis (and therefore heart attacks and strokes), chronic inflammation, Alzheimer's disease, Parkinson's disease and many others [1].
Our first goal is to create a a gene / enzyme therapy aimed at removing lipofuscin.
1
Therapy aimed at removing lipofuscin from the body will lead to:
Development of complex therapy for the removal of
intracellular junk from the human body
Improving the patient's condition in the presence of these pathologies
Improving the quality of life – well-being and activity in people over 40
Cosmetic therapy – elimination of liver spots, improvement of skin structure and elasticity
Reducing the risk of developing cardiovascular, neurodegenerative, oncological pathologies
2
Optimization of other types of rejuvenation therapies
Our second goal is to create a gene / enzyme therapy aimed at removing 7-ketocholesterol.
Therapy aimed at removing 7-ketocholesterol from the body will lead to:
Reducing chronic inflammation
Improving the quality of life – well-being and activity in people over 40
Reducing the risk of developing cardiovascular, neurodegenerative, oncological pathologies
Prevention and effective treatment of atherosclerosis
Optimization of other types of rejuvenation therapies
Our third goal is development of a comprehensive panel of primary ageing biomarkers
A comprehensive panel of ageing biomarkers will allow to:
Find out the real biological age of human organs and tissues
Correctly prescribe rejuvenating therapies and panels
Check the effectiveness of rejuvenating therapies and panels
Help in the development of new rejuvenating therapies and panels
In the modern world, movements associated with maintaining health and prolonging an active life are gaining more and more popularity.
Many companies offer "rejuvenation procedures." However, how do you know if your body become really younger?
Many resources suggest determining the biological age by the complex of biochemical and physiological markers of the work of various organs (the study of liver and kidney enzymes, indicators of heart function, endurance, and others).
However, many such markers can be influenced by nutrition, lifestyle and drugs.
In humans, the liver enzymes, heart rate, kidney function and others can be temporarily normalized. Using stimulants, you can temporarily improve the mental and physical performance of the body.
But all this does not mean that your organism became younger.
Moreover, many aggressive therapies (for example, injections of growth hormone in middle age) are comparable with the inclusion of afterburner on a worn engine and they, temporarily improving the special set of "biomarkers", in the long term worsen health and shorten life.
How to solve the problem? It is necessary to quantitatively study the molecular and cellular damage that constantly form and accumulate in the body, but do not decrease by themselves. Damage, the totality of which leads to the ageing of the body. In other words, to use types of molecular and cellular damage themselves, which are the causes of age-related diseases, as biomarkers of ageing.
CURRENT STAGE
RESULTS
Currently, our group is conducting a histological study of skin tissues, muscles (including heart), brain, and liver. We study lipofuscin granules in the materials. Based on the results of this stage, a histological atlas (virtual/physical) of lipofuscin content in different tissues in people of different ages/sex/with different chronic diseases will be released.
Photomicrography of the human seminal vesicles.
Man 55 years old
Photomicrography of the human seminal vesicles.
Man 55 years old
Photomicrography of the human heart muscle.
Woman 56 years old
Photomicrography of the human heart muscle.
Man 87 years old
Photomicrography of the human coronary artery. A massive atherosclerotic plaque with calcification.
Man 87 years old
Photomicrography of the human coronary artery. Thrombotic occlusion of the vessel on a background of the atherosclerotic process with the phenomenon of recanalization of the thrombus.
Man 87 years old
Photomicrography of the human coronary artery. A massive atherosclerotic plaque with almost complete occlusion of the vessel.
Woman 57 years old
TEAM
RESEARCH ASSISTANT
HEAD OF BIOINFORMATICS LAB
CHIEF EXECUTIVE OFFICER
CHIEF TECHNOLOGY OFFICER
CHIEF SCIENCE OFFICER
ADVISORY BOARD
SENS Research Foundation
Betterhumans
Oisín Biotechnologies
University of Liverpool
Alexander Morozov
Radiologist, scientist, popularizer of innovative technologies and bioengineering. Over 20 scientific papers, 11 patents.

Started career in medicine in 2007, entering the Belarusian State Medical University at the Faculty of Medicine. In 2012, at the 6th year he was enrolled in the subordinate of the specialty "General Medicine" in the direction "Therapy".
CHIEF MEDICAL OFFICER
Winner of the:
• ХIХ Republican contest of scientific works of students of the Republic of Belarus,
• VII International Pirogov Scientific Medical Conference of Students and Young Scientists,
• V Student International Correspondence Scientific and Practical Conference,
• 66th scientific and practical conference of students and young scientists "Actual problems of modern medicine".

Received a grant for a scientific approach and innovativeness at International Pirogov Scientific Medical Conference.

In 2012-2013 was a member of the Council of the Belarusian State Medical University.

In 2013-2014 completed an internship at the state institution "Republican clinical medical center" of Administration President of Belarus. After that worked as a general practitioner.

In 2015 finished advanced training courses at the Belarusian Medical Academy for Postgraduate Education under the program "Emergency Conditions in the Clinic of Internal Medicine".
In 2016 finished retraining program with a degree in Ultrasound Diagnostics at the Belarusian Medical Academy for Postgraduate Education.
In 2018 finished retraining program with a degree in Radiology at the Belarusian Medical Academy for Postgraduate Education.

During work attended international medical conferences, where made presentations on the application of the latest technologies in the diagnosis of various pathologies, as well as studying the nature of pathological changes in the liver tissues in pathologies that manifest as fibrosis.

In 2015 created the popular science resource Future Collector, where, in addition to highlighting technological achievements and the development prospects of various fields of science, he carries out educational work in the field of anti-aging biotechnology and regenerative medicine.
Ariel Feinerman
Ariel began his career as an entomologist in 2003, enrolling in the Kaliningrad State Technical University at the programme Aquatic Bioresources and Aquaculture. He was engaged in the study of aquatic insects. He took part in several expeditions to the rivers of the Kaliningrad region and the North Caucasus.
CHIEF SCIENCE OFFICER
In 2006, he switched to learning programming. From 2010 to 2014 he worked as a software engineer. He took part in the development of games, computer graphics and sound processing.

In 2014, he enrolled in the Physics Department of Saint Petersburg State University. In 2015 he completed a practice in PCR, Real-time PCR, DNA Gel Electrophoresis at the Faculty of Biology in the Laboratory of Plant Genetic Engineering. In 2015 – 2016 he completed a practice in genetic engineering at the Faculty of Biology in the Laboratory of Physiological Genetics. Participated in the screening of yeast genomes. Participated in the testing of metal complexes for toxicity and biological activity using bacterial strains.

In 2017, he transferred to the Baltic Federal University and continued his studies at the programme Physics at the Institute of Physical and Mathematical Sciences and Information Technology. He studied biological molecules using NMR spectroscopy.

In 2017 – 2018, he worked as a consultant in a bioengineering company.

In 2017, he began work on education in the field of rejuvenation biotechnology and regenerative medicine. Deputy chief editor of the popular science resource Future Collector.

In 2019, he received a BS in physics for the study of phospholipids using low-field NMR spectroscopy.
Yevgen Haletskyi
MSc in Computer Science.
MSc in Bioinformatics and Structural Biology.

Over 15 years of experience in software development and project management. Strong technical skills in different areas.

Passion for science, self-education in biology, bioinformatics and longevity technologies.
CHIEF EXECUTIVE OFFICER
Alex Kadet
Alex is an internationally experienced Strategy and Business Development professional, leveraging 6+ years of managerial experience and passion for science aspiring to apply market power to end age-related diseases.

He started his career in PwC, then built and rebuilt companies from scratch, starting with consumer goods companies in Russia.

Also, he successfully co-founded a socially responsible startup.

Last 2 years he worked as Head of Business Development in Health- and BioTech startups, digging deep into the Longevity industry.
CHIEF EXECUTIVE OFFICER
Dr. Aubrey de Grey
Dr. Aubrey de Grey is the biomedical gerontologist who devised the SENS platform, and established SENS Research Foundation.
He is the Chief Science Officer of the SENS Research Foundation and VP of New Technology Discovery at AgeX Therapeutics, Inc.

Received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively.

Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.

He is the author of the book "Ending Aging".
SENS Research Foundation
James W. Clement
James Clement has devoted the last two decades to the science of life extension.

He is best known for his Supercentenarian Study, which has received international press (see Betterhumans Supercentenarian Research Study in the News) in addition to a feature story in the New York Times by Pulitzer Prize–winning writer Amy Harmon.

A champion of the transhumanist movement, he is the founder of the Betterhumans non-profit, which is the world's first specifically transhumanist biomedical research organization. Led by a collection of high-profile researchers, the organization focuses on bringing cutting edge scientific discoveries from the lab to the clinic, so that humanity can take advantage of these breakthroughs in a safe and inexpensive manner, as quickly as possible.
CEO and Research Scientist at Betterhumans.org

Gary Hudson
Gary Hudson is Executive Chairman and co-founder of Oisín Biotechnologies.

Mr Hudson is also active in several non-profits focusing on age-related disease. He provided seed funding for the SENS Research Foundation which is transforming the way the world researches and treats age-related disease. He is a major donor to and serves as an advisor to the Methuselah Foundation, dedicated to extending the healthy human lifespan by advancing tissue engineering and regenerative medicine therapies.

Prior to Oisin, Mr Hudson has worked extensively in the field of commercial space successfully starting and growing several companies. He is best known as the founder of Rotary Rocket, which built a landing test simulator for a reusable rocket that flew three successful flights in 1999. He has won several awards during his career including Laurel Award from Aviation Week and Space Technology, the Founder's Award from the Space Frontier Foundation and was inducted into the International Space Hall of Fame in 2014 for his contributions to the field. Mr Hudson currently is the President of the Space Studies Institute, a non-profit dedicated to commercial space flight and human space travel.
Executive Chairman at Oisín Biotechnologies
Ilia Mazunin
PhD in Biology, Molecular Genetics.

Senior Research Scientist in Skolkovo Institute of Science and Technology (Skoltech) and Center of Life Sciences.

Skills and Expertise:
• Genome Engineering
• Synthetic Biology
• Mitochondrial DNA
• Mitochondrial Diseases

Profiles:
Skoltech
ResearchGate


CHIEF TECHNOLOGY OFFICER
Dzerassa Gurtsieva
Dzerassa is currently reaching her BS in Biological Sciences at North-Ossetian State University. On the 4th year of study she moved in Pushchino to lead her diploma investigation in the Institute of Protein Research of Russian Academy of Sciences.

She believes that humanity is able to win the war against ageing and wish to work in rejuvenation biotechnology to make it real.

Dzerassa is keen on immunotherapy, biomedical research and protein engineering.
RESEARCH ASSISTANT
Nicholas DeLateur
Dr. Nicholas DeLateur is co-founder and Chief Scientific Officer of Revel Pharmaceuticals.

Nicholas DeLateur joined Revel at the beginning of 2020 as Revel's Chief Scientist. He believes in the revolutionary power of enzymes to catalyze new medicines and brings more than 10 years of experience in molecular biology and protein science.

Nicholas DeLateur earned his BS and MS in Chemistry at Northeastern University advised by Professors Mary Ondrechen and Penny Beuning, where he was awarded both NSF REU and Matz Biotechnology Scholarships. He completed his PhD in Chemistry at MIT advised by Professor Ron Weiss.

His work is focused on synthetic biology, protein engineering and quorum sensing with collaborations across labs at University of Illinois, University of Pennsylvania, Boston University and University of California LA.

Revel Pharmaceuticals
Dr. João Pedro de Magalhães
Professor João Pedro de Magalhães graduated in Microbiology in 1999 from the Escola Superior de Biotecnologia in his hometown of Porto, Portugal, and in 2004 obtained a PhD in Biological Sciences from the University of Namur in Belgium.
Following further training in genetics at Harvard Medical School (Boston, USA), in 2008 Prof de Magalhães joined the University of Liverpool in the UK and established the Integrative Genomics of Ageing group. His research on genetics, ageing and longevity has been widely featured in scientific magazines (Science, Nature, Scientific American, New Scientist, etc.), and he has published over 100 scientific papers.

Prof de Magalhães is a world-leader in big data and computational analyses, including genomics and machine learning, in ageing, longevity and age-related diseases. In addition, he has a longterm interest in technological trends and their future impact on society. His work on predicting how technology will shape the human condition has been published in magazines such as Futures and The Futurist, and in newspapers like The Independent.

Prof de Magalhães has given over 100 invited talks in international conferences, including three TEDx talks, and in many academic institutions and companies (e.g., Google's Calico and Allianz). He also makes regular media appearances (BBC, CNN, the Washington Post, the Financial Times and many others).

Prof de Magalhães is an advisor/consultant for various organizations, including nonprofit foundations and charities, universities, investment funds and biotech companies.

He is Chief Scientific Officer of Centaura, an ambitious biotech company in Switzerland focused on healthy ageing, and founded his own his company Magellan Science Ltd.
Principal Investigator at Integrative Genomics of Ageing Group, University of Liverpool
Konstantin Popadin, PhD
Konstantin Popadin earned his PhD from Lomonosov Moscow State University, Russia, where he focused on evolutionary and population genetics, including the mathematical and statistical tools behind them. He then sharpened his expertise in ageing biology at Harvard Medical School, Boston, USA, exploring the critical role of mitochondria in the ageing process. Afterward, at key institutions in Switzerland – Geneva Medical School, the Center for Comparative Genomics in Lausanne, and the School of Life Sciences at EPFL – he mastered large-scale population data analysis using cutting-edge technologies, including genome and transcriptome sequencing, advancing both applied and basic research.

In 2017 he established his own international research group MitoFunGen, focusing on the mitochondrial component of ageing and age-related diseases. His primary focus is understanding the mechanisms behind the rapid mtDNA somatic mutagenesis linked to ageing and finding strategies to mitigate it.

Konstantin has led interdisciplinary teams across borders, investigating mitochondrial germ line and somatic mutations, and mutational burden, to unravel the complex biological processes tied to ageing. His expertise spans from fundamental genome research on longevity to practical, data-driven applications with significant implications for global health.

HEAD OF BIOINFORMATICS LAB
    Contact us!
    © 2020 - 2024 IntraClear Biologics OÜ
    Registry code: 14994429
    Harju maakond, Tallinn, Kesklinna linnaosa, Pärnu mnt 139c-14, 11317
    +371(2)6961659
    info@intraclearbiologics.com